1. Home
  2. PRAX vs MCB Comparison

PRAX vs MCB Comparison

Compare PRAX & MCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRAX
  • MCB
  • Stock Information
  • Founded
  • PRAX 2015
  • MCB 1999
  • Country
  • PRAX United States
  • MCB United States
  • Employees
  • PRAX N/A
  • MCB N/A
  • Industry
  • PRAX Biotechnology: Pharmaceutical Preparations
  • MCB Major Banks
  • Sector
  • PRAX Health Care
  • MCB Finance
  • Exchange
  • PRAX Nasdaq
  • MCB Nasdaq
  • Market Cap
  • PRAX 599.7M
  • MCB 614.4M
  • IPO Year
  • PRAX 2020
  • MCB 2017
  • Fundamental
  • Price
  • PRAX $38.55
  • MCB $64.69
  • Analyst Decision
  • PRAX Strong Buy
  • MCB Buy
  • Analyst Count
  • PRAX 10
  • MCB 3
  • Target Price
  • PRAX $116.50
  • MCB $76.33
  • AVG Volume (30 Days)
  • PRAX 320.6K
  • MCB 81.3K
  • Earning Date
  • PRAX 05-02-2025
  • MCB 07-17-2025
  • Dividend Yield
  • PRAX N/A
  • MCB N/A
  • EPS Growth
  • PRAX N/A
  • MCB N/A
  • EPS
  • PRAX N/A
  • MCB 5.92
  • Revenue
  • PRAX $8,122,000.00
  • MCB $270,555,000.00
  • Revenue This Year
  • PRAX N/A
  • MCB $10.80
  • Revenue Next Year
  • PRAX N/A
  • MCB $11.86
  • P/E Ratio
  • PRAX N/A
  • MCB $10.92
  • Revenue Growth
  • PRAX 270.02
  • MCB 12.84
  • 52 Week Low
  • PRAX $26.70
  • MCB $37.10
  • 52 Week High
  • PRAX $91.83
  • MCB $69.56
  • Technical
  • Relative Strength Index (RSI)
  • PRAX 53.72
  • MCB 55.41
  • Support Level
  • PRAX $35.21
  • MCB $63.69
  • Resistance Level
  • PRAX $38.90
  • MCB $66.05
  • Average True Range (ATR)
  • PRAX 2.09
  • MCB 1.55
  • MACD
  • PRAX 0.07
  • MCB -0.53
  • Stochastic Oscillator
  • PRAX 69.58
  • MCB 34.25

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

Share on Social Networks: